Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 5/20 | 0.48 |
| ▸ | F10 | P00742 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7528550 | 1.00 | KDM4E (0.51) | KDM4EALDH1A1HPGDPOLBAPP | |
| SCHEMBL7648400 | 0.94 | MAPT (0.54) | KDM4EALDH1A1HPGDPOLBAPP | |
| SCHEMBL7647418 | 0.94 | APP (0.49) | KDM4EALDH1A1HPGDPOLBAPP | |
| SCHEMBL7647393 | 0.94 | APP (0.49) | KDM4EALDH1A1HPGDPOLBAPP | |
| SCHEMBL7529846 | 0.91 | APP (0.47) | KDM4EALDH1A1HPGDAPPMAPT | |
| SCHEMBL7529853 | 0.91 | APP (0.47) | KDM4EALDH1A1HPGDAPPMAPT | |
| SCHEMBL7527657 | 0.90 | TSHR (0.50) | KDM4EALDH1A1HPGDAPPMAPT | |
| SCHEMBL7527663 | 0.90 | TSHR (0.50) | KDM4EALDH1A1HPGDAPPMAPT | |
| SCHEMBL7527359 | 0.88 | MAPT (0.56) | APPF10MAPTSNCANPC1 | |
| SCHEMBL7645682 | 0.88 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDPOLBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-18 | — | — | US | claimed |
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | TELIK, INC. | 2002-03-14 | — | — | US | claimed |
| US-6479548-B2 | P-(BENZOYLAMINO)STILBENE DERIVATIVES | TELIK, INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | TELIK, INC. | 2002-03-14 | — | — | US | disclosed |
| US-6303609-B1 | USED FOR THE INHIBITION OF PLATELET AGGREGATION, AS THROMBOLYTICS, AND/OR FOR THE TREATMENT OF THROMBOEMBOLIC DISORDERS | DUPONT PHARMACEUTICALS COMPANY | 2001-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094978-A1 | Novel isoxazoline fibrinogen receptor antagonists | F13B, F11, FGB | KDM4E 4702/4885ALDH1A1 702/4885HPGD 858/4885 |
| US-20020032218-A1 | Substituted stilbenes as glucose uptake enhancers | SLC2A1, SLC2A8, SLC2A2 | KDM4E 3079/4885ALDH1A1 1811/4885HPGD 2770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.